Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 19, Issue 11, Pages 1055-1067Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2019.1643237
Keywords
NMDA receptor; ketamine; depression; antidepressant; antagonist
Categories
Funding
- National Science Centre, Poland [2015/19/B/NZ4/01890]
- Statutory activity of the Maj Institute of Pharmacology Polish Academy of Sciences in Krakow, Poland
Ask authors/readers for more resources
Introduction: Current antidepressant therapies exhibit low therapeutic efficiency and delayed onset of antidepressant action. Thus, the search for better acting agents is a continuous process. One of the primary targets for the development of new antidepressant drugs is the glutamate N-methyl-D-aspartate (NMDA) receptor. Areas covered: The present review aims to summarize and provide an update on published preclinical data evaluating the antidepressant efficacy of various NMDA antagonists and their mechanisms of action. The review also provides an update on the clinical efficacy of ketamine and esketamine as well as other NMDA receptor antagonists based on published results from clinical studies. Expert opinion: The recent approval of esketamine by the FDA for the treatment of major depressive disorder (MDD) culminates the almost 30 years of research focused on the NMDA receptor as a target for the development of antidepressants. This action gives hope to patients who do not respond to currently available pharmacotherapy. While knowledge of the mechanism of action of ketamine/esketamine will pave the way for the creation of a new class of antidepressants, recent results have shown that several issues regarding the use of these compounds or other NMDA receptor antagonists must be clarified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available